echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Selpercatinib can be expected in RET fusion-positive solid tumors

    Lancet Oncol: Selpercatinib can be expected in RET fusion-positive solid tumors

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Selpercatinib is a first-line highly selective RET kinase inhibitor with CNS activity that has shown efficacy


    The LIBRETTO-001 study was designed to assess the efficacy and safety


    The study was an ongoing 1/2, single-group, open-label basket trial of cancer patients aged 18 years (or ≥ 12 years, with regulatory authority permission) who had progressed after previous treatment with RET variants or did not have satisfactory treatment options, and administered Selpercatinib orally, and in the phase 1 dose increment, patients received Selpercatinib 20 mg/day or 20-240 mg*2 times/day; The recommended dose for Phase 2 is 160 mg*2 times/day


    Between December 4, 2017 and August 4, 2021, a total of 45 RET fusion-positive cancer patients



    Among the 41 patients whose efficacy could be evaluated, the objective response rate was 43.


    In summary, Selpercatinib showed clinically significant activity in patients with RET fusion-positive tumors, and its safety was consistent


    Original Source:

    Vivek Subbiah, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.